Join us to discuss the new cancer hospital proposed by Dana-Farber

Dana-Farber Cancer Institute shared a post on LinkedIn:

”Join us to discuss the new cancer hospital proposed by Dana-Farber.

The Boston Planning and Development Agency will hold a joint IMP Task Force/Community Meeting to review Dana-Farber Cancer Institute’s recently submitted Institutional Master Plan (IMP) on July 29, 2024, at 6 pm via Zoom.

This meeting is an opportunity for the IMP Task Force and the public to review Dana-Farber’s IMP, which includes a new cancer hospital.

The purpose of the meeting is to discuss the IMP and identify any potential impacts. The meeting will include a presentation followed by questions and comments from the Task Force and the public.

To register to attend the meeting.”

Source: Dana-Farber Cancer Institute/LinkedIn

Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a leading institution for cancer treatment and research. It was founded by Sidney Farber on 1947. Currently, the Institute has over 5,000 staff, faculty, and clinicians on board. They manage in excess of 640,000 outpatient visits each year, oversee more than 1,000 hospital discharges annually, and are actively involved in over 1,100 ongoing clinical trials.

As of 2023, Dana-Farber is ranked as the #4 cancer hospital globally. Dana-Farber’s research contributions include the development of Gleevec, a highly successful treatment for chronic myeloid leukemia.